GenoMed (PINKSHEETS: GMED), a Next-Generation
Disease Management company whose business is public health(TM), today
joined Sgt. Donnie Manry, a Bryan, Texas policeman recovering from
paralysis due to West Nile virus, in urging greater public awareness of
GenoMed’s clinical trial for West Nile virus encephalitis.
Sgt. Manry contracted West Nile virus encephalitis in July 2006, becoming
paralyzed from the waist down. Three weeks after his first symptoms, Sgt.
Manry and his physician began GenoMed’s treatment protocol, which they
credit with speeding his recovery. But despite heroic effort, Sgt. Manry
still cannot walk without assistance nearly a year later.
Sgt. Manry, who is scheduled to lose his police job in two months because
of his continued paralysis, said, “I don’t want anybody to have to go
through what I did. I just wish I’d known about GenoMed’s protocol sooner.”
Added Sgt. Manry, “In my case it took over a week before West Nile virus
was even confirmed. GenoMed’s treatment should be started as a
precautionary measure even before confirmation by the CDC lab.”
Said GenoMed’s CEO and Chief Medical Officer, David Moskowitz MD, “Mr.
Manry has put in a superhuman effort to recover from this devastating
disease, which has been well documented
( http://www.topix.net/search/article?q=%22Donnie+Manry%22 , and
http://www.donniemanry.info ). Our experience with other patients suggests
that he would have gotten a lot better a lot faster if he’d begun our
treatment right away, within the first two days rather than three weeks
later.”
Added Dr. Moskowitz, “The sooner brain inflammation is turned off, the
lower the risk of paralysis. Knowing about our treatment ahead of time
could make the difference between a quick recovery instead of prolonged
paralysis.”
About GenoMed
Since 2003, GenoMed has been using safe, already existing,
prescription-only blood pressure pills to treat West Nile virus
encephalitis. So far, GenoMed has had an 83% treatment success rate (20 of
24 patients). The first 8 patients were published three years ago in a
peer-reviewed medical journal. GenoMed still has the only published
treatment for West Nile virus encephalitis in the medical literature. Last
summer GenoMed extended its trial successfully to include horses. Anyone
can download the WNV trial protocol from GenoMed’s website,
www.genomed.com , by clicking on the “West Nile trial” link. An email
address is required for clinical follow-up.
Safe Harbor Statement
This press release contains forward-looking statements, including those
statements pertaining to GenoMed, Inc.’s (the Company’s) treatments. The
words or phrases “ought to,” “should,” “could,” “may,” or similar
expressions are intended to identify “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of 1995. Actual
results could differ materially from those projected in the
forward-looking statements as a result of a number of risks and
uncertainties, including but not limited to our research and development
being subject to scientific, economic, regulatory, governmental, and
technological factors. Statements made herein are as of the date of this
press release and should not be relied upon as of any subsequent date.
Unless otherwise required by applicable law, we specifically disclaim any
obligation to update any forward-looking statements to reflect occurrences,
developments, unanticipated events or circumstances after the date of such
statement.
David W. Moskowitz MD
CEO
GenoMed
tel. 314.983.9933
dwmoskowitz@genomed.com
Information provided by: Findarticles.com
